We are live on
!
Find out more
Madrigal Pharmaceuticals
MDGL
MDGL
205 hedge funds and large institutions have $2.54B invested in Madrigal Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 89 increasing their positions, 54 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
102% more call options, than puts
Call options by funds: $225M | Put options by funds: $111M
65% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 54
12.83% more ownership
Funds ownership: 81.18% → 94.02% (+13%)
3% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 38
1% less funds holding
Funds holding: 208 → 205 (-3)
26% less capital invested
Capital invested by funds: $3.43B → $2.54B (-$890M)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Holders
205
Holders Change
-3
Holders Change %
-1.44%
% of All Funds
3.25%
Holding in Top 10
6
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
37
Increased
89
Reduced
54
Closed
38
Calls
$225M
Puts
$111M
Net Calls
+$114M
Net Calls Change
-$65.8M
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$293M |
| 2 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$45.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$38.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$36.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.5M |
Top Sellers
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$79.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$33.6M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$19.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$15.7M |
| 5 |
O
OrbiMed
New York
|
-$12.8M |
